Literature DB >> 35782817

Salvaging the Unsalvageable Giant Cell Tumors of Bone: The 'Longitudinal Sandwich Technique'.

Rishi Ram Poudel1, Akshay Tiwari2, Aakriti Jain2, Vivek Verma2.   

Abstract

Management of Campanacci Grade III Giant Cell Tumors of bone (GCT) is challenging. Although selected cases of Grade III GCTs can still be managed with intralesional extended curettage, wide excision of the lesion is usually recommended when there is extensive cortical destruction. This study describes the outcome of 'longitudinal sandwich technique' for extended curettage of Grade III GCTs with more than 50% cortical destruction. Here, the deficiency of cortex was made up for by using bone graft/graft substitute, used alongside cement placed in a longitudinal fashion. Twelve patients operated with this technique between Jan 2012 and Jan 2018 were reviewed. Majority of the lesions involved the lower limbs. Bone graft was used in eight whereas commercial bone graft substitute was used in the remaining four, along with bone cement in all. On follow-up ranging from 38 to 84 months (median follow-up 59 months), there were 4 local recurrences (33.33%). All recurrences were managed successfully with repeat surgery without the need for bony resection. Mean MSTS score during the last follow-up was 25.08 ± 2.31 and all patients were disease-free during the last follow-up. 'Longitudinal sandwich technique' helps to expand the indications of extended curettage even for aggressive Grade III GCTs, with satisfactory outcomes.
© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2022.

Entities:  

Keywords:  Extended curettage; Giant cell tumor; Longitudinal sandwich technique

Year:  2022        PMID: 35782817      PMCID: PMC9240147          DOI: 10.1007/s13193-022-01545-3

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  28 in total

1.  Management of grade III giant cell tumors of bones.

Authors:  Hsien-Chung Wang; Song-Hsiung Chien; Gau-Tyan Lin
Journal:  J Surg Oncol       Date:  2005-10-01       Impact factor: 3.454

2.  Giant-cell tumor: a study of 195 cases.

Authors:  D C Dahlin; R E Cupps; E W Johnson
Journal:  Cancer       Date:  1970-05       Impact factor: 6.860

3.  Treatment of stages 2 and 3 giant-cell tumor.

Authors:  K Labs; C Perka; R G Schmidt
Journal:  Arch Orthop Trauma Surg       Date:  2001       Impact factor: 3.067

Review 4.  The clinical approach toward giant cell tumor of bone.

Authors:  Lizz van der Heijden; P D Sander Dijkstra; Michiel A J van de Sande; Judith R Kroep; Remi A Nout; Carla S P van Rijswijk; Judith V M G Bovée; Pancras C W Hogendoorn; Hans Gelderblom
Journal:  Oncologist       Date:  2014-04-09

5.  Giant cell tumor of bone: risk factors for recurrence.

Authors:  Frank M Klenke; Doris E Wenger; Carrie Y Inwards; Peter S Rose; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2010-08-13       Impact factor: 4.176

6.  Features of grade 3 giant cell tumors of the distal radius associated with successful intralesional treatment.

Authors:  Lana Kang; Mark W Manoso; Patrick J Boland; John H Healey; Edward A Athanasian
Journal:  J Hand Surg Am       Date:  2010-10-08       Impact factor: 2.230

7.  Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.

Authors:  A Puri; A Gulia; P Hegde; V Verma; B Rekhi
Journal:  Bone Joint J       Date:  2019-02       Impact factor: 5.082

8.  Survival of modern knee tumor megaprostheses: failures, functional results, and a comparative statistical analysis.

Authors:  Elisa Pala; Giulia Trovarelli; Teresa Calabrò; Andrea Angelini; Caterina N Abati; Pietro Ruggieri
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

9.  Wide resection versus curettage in giant cell tumor with pathological fracture? A systematic review and meta-analysis.

Authors:  Abhijeet Ashok Salunke; Subodh Pathak; Jaymin Shah; Jyotindra Pandit; Vinod Naneria
Journal:  J Clin Orthop Trauma       Date:  2017-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.